Katie Thaxton, MSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 810 E Angie Ave, Medical Lake, WA 99022 Phone: 586-321-7265 |
News Archive
In today's news, more reports regarding the health reform provisions that took effect yesterday and more details on the GOP's "Pledge To America."
Salix Pharmaceuticals, Ltd. today announced the successful outcome of two Phase 3, randomized, double-blind, placebo-controlled, multicenter trials, TARGET 1 and TARGET 2, designed to evaluate the efficacy and safety of rifaximin 550 mg TID in the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS).
Today, invasive animals and plants spread all around the globe. Predicting the dynamics of these invasions is of great ecological and socioeconomical interest. Yet studying them is fundamentally challenging because of the large spatial and temporal scales involved. Scientists at Eawag and University of Zurich are now using computer simulations and small artificial laboratory worlds, to study how rapid evolution makes invaders spread even faster.
The U.S. Food and Drug Administration today approved Prevnar 13, a pneumococcal 13-valent conjugate vaccine for infants and young children ages 6 weeks through 5 years. Prevnar 13 will be the successor to Prevnar, the pneumococcal 7-valent conjugate vaccine licensed by the FDA in 2000 to prevent invasive pneumococcal disease (IPD) and otitis media. The new vaccine extends the protection to six additional types of the disease causing bacteria.
› Verified 4 days ago